5-bromo-6-(2-methoxyethoxy)-pyridin-3-amine | 1198319-47-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-bromo-6-(2-methoxyethoxy)-pyridin-3-amine
• 英文别名: 5-bromo-6-(2-methoxy-ethoxy)-pyridin-3-ylamine；5-Bromo-6-(2-methoxyethoxy)pyridin-3-amine
• CAS: 1198319-47-9
• 化学式: C₈H₁₁BrN₂O₂
• 分子量: 247.092
• InChiKey: LCSCVOZYNAKWJK-UHFFFAOYSA-N

物化性质

• 沸点：
  348.7±42.0 °C(Predicted)
• 密度：
  1.502±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  57.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-bromo-6-(2-methoxyethoxy)-pyridin-3-amine 在 四(三苯基膦)钯 溴 、 二正丁基氧化锡 、 sodium carbonate 、 溶剂黄146 、 三乙胺 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 甲苯 为溶剂， 反应 2.08h， 生成 1-ethyl-3-[5-(2-methoxyethoxy)-6-pyrimidin-5-yl[1,3]thiazolo[5,4-b]pyridin-2-yl]urea
  参考文献：
  名称：

  [EN] THIAZOLO [5, 4-B] PYRIDINE AND OXAZOLO [5, 4-B] PYRIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS
  [FR] DÉRIVÉS DE THIAZOLO [5, 4-B] PYRIDINE ET D'OXAZOLO [5,4-B] COMME AGENTS ANTIBACTÉRIENS

  摘要：

  描述了化学式（I）的化合物及其药用可接受的盐。还描述了它们的制备方法、含有它们的药物组合物、它们作为药物的用途以及它们在治疗细菌感染中的用途。

  公开号：

  WO2009147431A1
• 作为产物：
  描述：

  3-溴-2-氯-5-硝基吡啶 在 potassium carbonate 、 氯化铵 、 锌 作用下， 以 水 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 11.0h， 生成 5-bromo-6-(2-methoxyethoxy)-pyridin-3-amine
  参考文献：
  名称：

  [EN] THIAZOLO [5, 4-B] PYRIDINE AND OXAZOLO [5, 4-B] PYRIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS
  [FR] DÉRIVÉS DE THIAZOLO [5, 4-B] PYRIDINE ET D'OXAZOLO [5,4-B] COMME AGENTS ANTIBACTÉRIENS

  摘要：

  描述了化学式（I）的化合物及其药用可接受的盐。还描述了它们的制备方法、含有它们的药物组合物、它们作为药物的用途以及它们在治疗细菌感染中的用途。

  公开号：

  WO2009147431A1

文献信息

• N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES
  申请人：Grether Uwe

  公开号：US20120094993A1

  公开（公告）日：2012-04-19

  The present invention relates to compounds of formula I, wherein A, R 1 to R 7 are defined in the description, and to pharmaceutically acceptable salts thereof. The present invention also relates to the manufacture of such compounds or their pharmaceutically acceptable salts, pharmaceutical compositions containing them and their use as medicaments for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as dyslipidemia, atherosclerosis and cardiovascular diseases.

  本发明涉及式I的化合物，其中A，R1至R7在说明中有定义，并且其药学上可接受的盐。本发明还涉及制备这种化合物或其药学上可接受的盐，含有它们的药物组合物以及将它们用作治疗和/或预防可以使用HDL胆固醇升高剂治疗的疾病的药物，如脂质代谢异常、动脉粥样硬化和心血管疾病。
• [EN] N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES<br/>[FR] N-PYRIDIN-3-YL- OU N-PYRAZIN-2-YL-CARBOXAMIDES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012049190A1

  公开（公告）日：2012-04-19

  The present invention relates to compounds of the formula I wherein A, R1 to R7 are defined in the description, and to pharmaceutically acceptable salts thereof, their manufacture, pharmaceutical compositions containing them and their use as medicaments for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as particularly dyslipidemia, atherosclerosis and cardiovascular diseases.

  本发明涉及公式I的化合物，其中A，R1至R7在描述中有定义，并且其药学上可接受的盐，它们的制备，含有它们的药物组合物以及它们作为治疗和/或预防可用高密度脂蛋白胆固醇升高剂治疗的疾病的药物的用途，如特别是脂质代谢异常，动脉粥样硬化和心血管疾病。
• NEW COMPOUND 255
  申请人：Ghorpade Sandeep Raghunath

  公开号：US20100137303A1

  公开（公告）日：2010-06-03

  Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

  本文描述了化学式(I)的化合物及其药物可接受的盐。还描述了制备它们的过程，包含它们的制药组合物，以及它们作为药物用于治疗细菌感染的用途。
• N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
  申请人：Grether Uwe

  公开号：US08410107B2

  公开（公告）日：2013-04-02

  The present invention relates to compounds of formula I, wherein A, R1 to R7 are defined in the description, and to pharmaceutically acceptable salts thereof. The present invention also relates to the manufacture of such compounds or their pharmaceutically acceptable salts, pharmaceutical compositions containing them and their use as medicaments for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as dyslipidemia, atherosclerosis and cardiovascular diseases.

  本发明涉及式I的化合物，其中A，R1至R7在说明中定义，并且其药学上可接受的盐。本发明还涉及制备这样的化合物或其药学上可接受的盐，包含它们的制药组合物以及它们作为药物治疗和/或预防可用高密度脂蛋白胆固醇升高剂治疗的疾病，例如失调脂质症、动脉硬化和心血管疾病的用途。
• Thiazolopyridine Ureas as Novel Antitubercular Agents Acting through Inhibition of DNA Gyrase B
  作者：Manoj G. Kale、Anandkumar Raichurkar、Shahul Hameed P、David Waterson、David McKinney、M. R. Manjunatha、Usha Kranthi、Krishna Koushik、Lalit kumar Jena、Vikas Shinde、Suresh Rudrapatna、Shubhada Barde、Vaishali Humnabadkar、Prashanti Madhavapeddi、Halesha Basavarajappa、Anirban Ghosh、VK Ramya、Supreeth Guptha、Sreevalli Sharma、Prakash Vachaspati、K.N. Mahesh Kumar、Jayashree Giridhar、Jitendar Reddy、Vijender Panduga、Samit Ganguly、Vijaykamal Ahuja、Sheshagiri Gaonkar、C. N. Naveen Kumar、Derek Ogg、Julie A. Tucker、P. Ann Boriack-Sjodin、Sunita M. de Sousa、Vasan K. Sambandamurthy、Sandeep R. Ghorpade

  DOI：10.1021/jm401268f

  日期：2013.11.14

  A pharmacophore-based search led to the identification of thiazolopyridine ureas as a novel scaffold with antitubercular activity acting through inhibition of DNA Gyrase B (GyrB) ATPase. Evaluation of the binding mode of thiazolopyridines in a Mycobacterium tuberculosis (Mtb) GyrB homology model prompted exploration of the side chains at the thiazolopyridine ring C-5 position to access the ribose/solvent pocket. Potent compounds with GyrB IC50 ≤ 1 nM and Mtb MIC ≤ 0.1 μM were obtained with certain combinations of side chains at the C-5 position and heterocycles at the C-6 position of the thiazolopyridine core. Substitutions at C-5 also enabled optimization of the physicochemical properties. Representative compounds were cocrystallized with Streptococcus pneumoniae (Spn) ParE; these confirmed the binding modes predicted by the homology model. The target link to GyrB was confirmed by genetic mapping of the mutations conferring resistance to thiazolopyridine ureas. The compounds are bactericidal in vitro and efficacious in vivo in an acute murine model of tuberculosis.